Kolon Life Science’s osteoarthritis therapy ‘Invossa K’ landed in 60 general hospitals
‘Invossa,’ a gene therapy for osteoarthritis, will start to be prescribed in general hospitals.
Kolon Life Science(CEO Woo-Seok Lee) and Mundipharma(CEO Myung-Sae Lee) announced on the 11th that the world’s first and only ‘Invossa® K’ passed 60 major general hospitals’ drug committee as well as ...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.